SCHEMBL2002248

SCHEMBL2002248

Cc1ccc2nc(Oc3cc(N)cc(Cl)c3)sc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.49
MAPT P10636 3/20 0.49
APP P05067 7/20 0.46
NPC1 O15118 4/20 0.46
KDM4E B2RXH2 2/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.39
ILK Q13418 1/20 0.38
PTPN1 P18031 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
LMNA P02545 1/20 0.36
DYRK1A Q13627 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2002218 0.88 APP (0.47) RAB9AMAPTAPPNPC1KDM4E
SCHEMBL2001182 0.86 CYP1A2 (0.55) RAB9AMAPTAPPNPC1SMN1; SMN2
SCHEMBL2002000 0.85 GFER (0.49) RAB9AMAPTAPPNPC1KDM4E
SCHEMBL12568205 0.83 CYP1A2 (0.49) RAB9AMAPTNPC1KDM4ESMN1; SMN2
SCHEMBL2004852 0.80 NPC1 (0.51) RAB9AMAPTNPC1KDM4EGAA
SCHEMBL2000944 0.80 LOXL2 (0.46) RAB9AMAPTAPPNPC1KDM4E
SCHEMBL11819226 0.77 SMN1; SMN2 (0.55) RAB9AMAPTAPPNPC1KDM4E
SCHEMBL2003772 0.76 ALDH1A1 (0.48) MAPTKDM4EGAASMN1; SMN2CYP3A4
SCHEMBL1997109 0.75 LMNA (0.50) RAB9AMAPTNPC1GAASMN1; SMN2
SCHEMBL21471191 0.75 CYP1A2 (0.49) RAB9AMAPTAPPNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960408-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2011-06-14 US disclosed
US-7601841-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2009-10-13 US disclosed
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. (US) 2009-09-03 US disclosed
EP-1296967-B1 BENZOTHIAZOLYL PPAR-GAMMA MODULATORS AMGEN INC (US) 2006-05-31 EP disclosed
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC 2004-09-09 US disclosed
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC. 2003-09-11 US disclosed
US-6583157-B2 Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders TULARIK INC. 2003-06-24 US disclosed
EP-1296967-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS Tularik Inc. (US) 2003-04-02 EP disclosed
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. 2002-11-14 US disclosed
WO-2002000633-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS TULARIK INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD RAB9A 1423/4885MAPT 3145/4885APP 3233/4885
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD RAB9A 1423/4885MAPT 3145/4885APP 3233/4885
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARA, PPARG, PPARD RAB9A 1423/4885MAPT 3145/4885APP 3233/4885
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARG, PPARA, PPARD RAB9A 1869/4885MAPT 3019/4885APP 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.